The DOI matches its Crossref record; 82 of the 83 references it cites were found in a registry or an index.
Current and future treatments for Alzheimer's disease
Open accessAbstract
Alzheimer's dementia (AD) is increasingly being recognized as one of the most important medical and social problems in older people in industrialized and non-industrialized nations. To date, only symptomatic treatments exist for this disease, all trying to counterbalance the neurotransmitter disturbance. Three cholinesterase inhibitors (CIs) are currently available and have been approved for the treatment of mild to moderate AD. A further therapeutic option available for moderate to severe AD is memantine, an N-methyl-D-aspartate receptor noncompetitive antagonist. Treatments capable of stopping or at least effectively modifying the course of AD, referred to as 'disease-modifying' drugs, are still under extensive research. To block the progression of the disease they have to interfere with the pathogenic steps responsible for the clinical symptoms, including the deposition of extracellular amyloid β plaques and intracellular neurofibrillary tangle formation, inflammation, oxidative damage, iron deregulation and cholesterol metabolism. In this review we discuss current symptomatic treatments and new potential disease-modifying therapies for AD that are currently being studied in phase I-III trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“After the sequential breakdown of the big precursor protein amyloid precursor protein (APP) by the β- and γ-e -secretase, Aβ peptides with A38, A40, and A42 being the most prevalent forms are generated (Yiannopoulou et al., 2013).”
From An update on the novel and approved drugs for Alzheimer disease (2022) · cites this paper as Yiannopoulou et al., 2013
In the citing paper
“Memantine is known to be a non-competitive NMDA receptor antagonist that counteracts the negative effects of high glutamate concentrations in the brain (Yiannopoulou et al., 2013).”
From An update on the novel and approved drugs for Alzheimer disease (2022) · cites this paper as Yiannopoulou et al., 2013
In the citing paper
“The most efficient and prospective class is passive Ab immunotherapy using mAbs. The chief disadvantages of this class of medicines are cerebral microhemorrhages and vasogenic edema (Yiannopoulou et al., 2013).”
From An update on the novel and approved drugs for Alzheimer disease (2022) · cites this paper as Yiannopoulou et al., 2013
In the citing paper
“Memantine is a noncompetitive low-affinity NMDA-receptor open-channel blocker and affects glutamatergic transmission.5”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“AChEIs attempt at reducing the breakdown of acetylcholine levels in the brain of the patients with AD by inhibiting the responsible enzyme acetylcholinesterase in the synaptic cleft.5”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“According to the “amyloid hypothesis” Aβ production in the brain initiates a cascade of events leading to the clinical syndrome of AD.”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“The basic pathophysiology and neuropathology of AD that drives the current research suggests that the primary histopathologic lesions of AD are the extracellular amyloid plaques and the intracellular Tau neurofibrillary tangles (NFTs).5”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“The elements of the cascade include local inflammation, oxidation, excitoxicity (excessive glutamate), and tau hyperphosphorylation.5”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“The acetylocholinesterase inhibitors (AChEIs) which are approved for the treatment of AD are donepezil, galantamine, and rivastigmine.4,5”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“It is the forming of amyloid oligomers to which neurotoxicity is mainly attributed and initiates the amyloid cascade.”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“Progressive neuronal destruction leads to shortage and imbalance between various neurotransmitters (eg, acetylcholine, dopamine, serotonin) and to the cognitive deficiencies seen in AD.5”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“A further therapeutic agent approved for moderate to severe AD is the low-to-moderate affinity, noncompetitive N-methyl-d-aspartate (NMDA) receptor antagonist memantine.4,5”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“The APP cleavage by α-secretase leads to nonamyloidogenic pathway, whereas APP cleavage by β-secretase (BACE1) leads to amyloidogenic pathway.”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“The Aβ derives from a protein overexpressed in AD, APP through sequential proteolysis by β-secretase (BACE1) in the extracellular domain and γ-secretase in the transmembrane region.”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“Sequential cleavage of APP by BACE1 in the extracellular and γ-secretase in the transmembrane area results in the Aβ production.”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“The crucial step in AD pathogenesis is the production of amyloid (Aβ), which forms SPs (insoluble and proteolysis-resistant fibrils).”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“Aβ40 is somewhat aggregation-prone and it is mostly found in the cerebral vasculature as a main component of “cerebral amyloid angiopathy.””
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“Oligomers can form Aβ-fibrils that will eventually form amyloid plaques.”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“Major sites of γ-secretase cleavage usually occur in positions 40 and 42 of Aβ, thus Aβ40 and Aβ42 oligomers are the main products of the sequential APP cleavage, as the amyloidogenic pathway is favored in neurons because of the greater plentifulness of BACE1.”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“Aβ40 usually constitutes more than 50% of total detected Aβ.”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“Unluckily, concerning γ-secretase, in addition to APP, this particular enzyme acts on many other substances and cleaves different transmembrane proteins. Notch receptor 1, which is essential for control of normal cell differentiation and communication, is among them.5”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“Aβ42 is the most aggregation-prone form and has the tendency to cluster into oligomers.”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“Aβ38 is soluble, present in the vasculature of patients with sporadic and familial AD.”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“On the contrary, the nonamyloidogenic processing is more favored in other cells without BACE1 predominance.5”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“Cerebral microhemorrhages and vasogenic edema are the main drawbacks in this group of agents.5”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“Abnormal accumulation or dyshomeostasis of metal ions such as iron, copper, and zinc has been associated with the pathophysiology of AD.5”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
The cholinergic hypothesis of geriatric memory dysfunction
Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982) · Science · doi:10.1126/science.7046051 · Cited by 5,545
Global prevalence of dementia: a Delphi consensus study
Ferri, C. P., Prince, M. J., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K. S., Hasegawa, K., Hendrie, H. C., Huang, Y., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67889-0 · Cited by 5,336
Cholinesterase inhibitors for Alzheimer's disease
Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906
Revising the definition of Alzheimer's disease: a new lexicon
Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869
Statins and the risk of dementia
Jick, H., Zornberg, G. L., Jick, S. S., Seshadri, S. S., & Drachman, D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03155-x · Cited by 1,764
Tariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S., Gergel, I., & for the Memantine Study Group (2004) · JAMA · doi:10.1001/jama.291.3.317 · Cited by 1,403
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329
McShane, R., Areosa Sastre, A., & Minakaran, N. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003154.pub5 · Cited by 1,155
Clinical trial of indomethacin in Alzheimer's disease
Rogers, J., Kirby, L., Hempelman, S. R., Berry, D. A., McGeer, P. L., Kaszniak, A. W., Zalinski, J., Cofield, M., Mansukhani, L., Willson, P., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1609 · Cited by 991
Research works printed but not linked: 6
- Alva G., 2008, Psychiatry (Edgmont), 5, 27
- Ballard C., 2010, CNS Drugs, 24, 729
- Cummings J., 2008, Primary Psychiatry, 15, 66
- Hansen R., 2008, Clin Interv Aging, 3, 211
- Hey J., Koelsch G., Bilcer G., Jacobs A., Tolar M., Tang J. (2008) Single dose administration of the b-secretase inhibitor CTS21166 (ASP1720) reduces plasma Aβ40 in human subjects. Presented by Dr Koelsch in the International Conference on Alzheimer’s Disease (ICAD), Chicago, IL, USA, 26–31 July 2008. Available at: http://www.alzforum.org/new/detail.asp?id=1790
- Yiannopoulou K., 2009, Primary Psychiatry, 16, 29
Cited by
Sorted by citations
Items 601–682 of 682
Fatima, R., Batool, A., & Ali, S. (2019) · Cross Current International Journal of Medical and Biosciences · doi:10.36344/ccijmb.2019.v01i02.002
A Alzheimer’s Disease Detection and Classification Using Customised Convolutional Neural Network
Mane, D., Patil, D., Sawant, M., Maiyani, K., & Patel, M. M. (2022) · Lecture notes on data engineering and communications technologies · doi:10.1007/978-981-19-3015-7_33
Jo, Y. S., Park, G., Jang, K., Bae, S., Kwon, Y. W., Lee, S., Jang, J., Lee, C., Oh, Y., & Yoon, J. H. (2022) · Research Square · doi:10.21203/rs.3.rs-2039843/v1
Neuropharmacology in Alzheimer and Huntington Disease
Gupta, B., & Rohatgi, K. (2022) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815040913122010015
Miculas, D. C., Ţiţ, D. M., Negru, P. A., Tarce, A. G., & Bungău, A. F. (2022) · Archives of the Balkan Medical Union · doi:10.31688/abmu.2022.57.3.06
Age-specific activation of microglial genes in a mouse model of ADPreprint
Zhou, H., & Yu, Y. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.28.514172
Circadian dysregulation and Alzheimer’s disease: A comprehensive review
Iacobelli, P. (2022) · Brain Science Advances · doi:10.26599/bsa.2022.9050021
Pereira, A. A. R. (2022) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.42.2022.tde-17112022-105850
NATURAL PRODUCT-BASED AMYLOID PROTEIN INHIBITORS
Swagath, S., & Suseem, S. R. (2022) · Innovare Journal of Sciences · doi:10.22159/ijs.2022.v10i1.41079
Multifunctional Nanoprobes for the Surveillance of Amyloid Aggregation
Jeyachandran, T., Loomba, S., Khalid, A., & Mahmood, N. (2023) · Springer eBooks · doi:10.1007/978-3-030-69023-6_105-1
Piauilino, E. N., Pereira, M. J. V., & Barros, V. D. J. C. (2023) · International Journal of Health Science · doi:10.22533/at.ed.15931323180210
A Review of the pharmacological treatments of Alzheimer’s disease (AD)
Jiang, D. F., & Xiao, Y. (2022) · Journal of Student Research · doi:10.47611/jsrhs.v11i3.3475
New Therapeutic Approaches for Sensory Symptoms in Alzheimer’s Disease
Reddy, C., & Madureira, M. (2022) · Journal of Student Research · doi:10.47611/jsrhs.v11i3.3793
Multifunctional Nanoprobes for the Surveillance of Amyloid Aggregation
Jeyachandran, T., Loomba, S., Khalid, A., & Mahmood, N. (2023) · Springer eBooks · doi:10.1007/978-3-031-16101-8_105
Tiwari, P. K., Geetha, K. M., Shrivastava, S., Kumari, Y., Panik, R. K., Singh, P. K., Kumar, D., & Sahu, P. K. (2023) · Frontiers in clinical drug research. CNS and neurological disorders · doi:10.2174/9789815123319123110006
Use of cannabidiol oil by caregivers: A focus on Alzheimer’s disease
Leszko, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-90036-2.00045-4
Lifestyle modifications and nutrition in Alzheimer's disease
Bhatti, G. K., Mishra, J., Sehrawat, A., Sharma, E., Kanozia, R., Navik, U., Reddy, P. H., & Bhatti, J. S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-89834-8.00049-0
Hybrid Approach for Alzheimer’s Disease Diagnosis For 3D Brain MR Image
Mudiraj, K. H., Arjun, N. S., & Reddy, K. S. (2023) · International Journal on Recent and Innovation Trends in Computing and Communication · doi:10.17762/ijritcc.v11i5s.6755
Liew, Y., Arulsamy, A., & Shaikh, M. F. (2023) · Springer eBooks · doi:10.1007/978-981-19-3949-5_50-1
Potential of stem cell therapy in phospholipase-mediated neurodegeneration
Kurian, G. A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-15177-4.00003-0
Vyshnavi, G., Swaroop, P. V. P., & Sornalakshmi, K. (2023) · International Conference on Recent Trends in Data Science and its Applications · doi:10.13052/rp-9788770040723.105
Exploring avenues for Alzheimer’s drugs: current status and future outlook
Rathi, K. M., Wavhale, R. D., V., V. U., Bhole, R. P., & Dherange, S. D. (2024) · Russian neurological Journal · doi:10.30629/2658-7947-2023-28-6-19-33
Blood brain barrier and its significance in drug delivery to brain in Alzheimer disease
Rana, D., Salave, S., Khunt, D., & Benival, D. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13205-6.00018-2 · Cited by 1
Zendehrouh, E., Sendi, M. S. E., Abrol, A., Batta, I., Hassanzadeh, R., & Calhoun, V. D. (2024) · medRxiv · doi:10.1101/2024.03.12.24303873
Relationship-centred care for people living with dementia in care homes. A rapid evidence summaryPreprint
Gillen, E., Edwards, D. J., Roberts, S. H., Davies, N., Davies, I., & Harden, J. (2024) · medRxiv · doi:10.1101/2024.04.15.24305839
Predicting Alzheimer's Onset through Neuroimaging
Kandula, N., Chakravarty, S., Kandula, A., & Mohapatra, S. K. (2024) · International Conference on Advancements in Smart, Secure and Intelligent Computing (ASSIC) · doi:10.1109/assic60049.2024.10507914
Arora, R., Rathore, K. S., & Saurabh, S. S. (2024) · International Journal of Pharmaceutical Chemistry and Analysis · doi:10.18231/j.ijpca.2024.019
Ramasahayam, S. R., Guggilla, S. S. S., & Loganathan, S. (2024) · AIP conference proceedings · doi:10.1063/5.0218095
Role of novel drug delivery systems in managing Alzheimer's disease
Chahat, Shome, A., & Chawla, P. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13474-6.00031-7
Liew, Y., Arulsamy, A., & Shaikh, M. F. (2024) · Springer eBooks · doi:10.1007/978-981-99-7557-0_50
Mohamed, N. H., & Lotfy, R. (2024) · Natural Product Research · doi:10.1080/14786419.2024.2424397
Evaluating Donanemab: Advances and Challenges in Alzheimer Disease Treatment
Shuja, M. H., Imran, H., Abid, M., & Ahmed, F. I. (2024) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001848
Role of Enzymes in Alzheimer’s Disease
Patel, S., Shrivastava, S., Marar, P. V., Swami, R., & Jeengar, M. K. (2024) · Springer eBooks · doi:10.1007/978-981-97-6822-6_2
Huang, X., Ji, Q., Tong, T., Cai, L., Elmadhoun, O., Zeng, Y., Geng, X., & Ding, Y. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1592829
Håkansson, E. O., Balestri, L. J. I., Sharathna, P., Moes, S., Henschel, H., Sköld, C., Hallberg, M., Larhed, M., Skillinghaug, B., & Odell, L. R. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00438a
Integrative Approach Towards Treatment of Alzheimer's and Other Dementias
Khan, N. A., Sambyal, N., Tanzeelah, Sachdeva, P., Siwan, D., Rehman, A., Dey, A., Ghosh, S., Mahajan, A. A., Rizvi, S., et al. (2025) · Advances in Integrative Medicine · doi:10.1002/9781394336807.ch8
Cicero, A. F. G., & Micoli, V. D. (2025) · Springer eBooks · doi:10.1007/978-3-031-93459-9_7
Machine Learning For Disease Biomarker Detection From Genome Expression Data
Surendran, P. (2024) · IEEE International Conference on Engineering Technologies and Applied Sciences (ICETAS) · doi:10.1109/icetas62372.2024.11119891
Why don’t we have a cure for Alzheimer’s disease?
Weaver, D. F. (2021) · doi:10.64628/aam.5xk75evke
ElSayed, M., Hassan, S. A., Raboh, T. A., AbdelGawad, I., Zoudy, S. I., & Shehata, I. M. (2025) · Research Square · doi:10.21203/rs.3.rs-7528339/v1
Andrade, E. J. N., Giraldi, L. D. A., Sudo, M. Y. R., Ramos, L. D. P., Salles, G. N., & Soares, C. P. (2025) · Research Square · doi:10.21203/rs.3.rs-8245044/v1
Unsupervised Cognitive Impairment Detection Using Convolutional Autoencoders and Isolation Forest
Salekshahrezaee, Z., & Khoshgoftaar, T. M. (2025) · IEEE International Conference on Information Reuse and Integration (IRI) · doi:10.1109/iri66576.2025.00062
Mohite, P., Bharti, D., & Gohri, V. (2025) · IGI Global eBooks · doi:10.4018/979-8-3373-4627-4.ch012
Zafar, I., Khan, M. S., Jamal, A., Shafiq, S., Bahwerth, F. S., & Khan, N. U. (2025) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2025.104070 · Cited by 1
Exploring boswellic acids as a multitarget therapeutic treatment for Alzheimer’s disease
Patil, D. N., & Barvkar, V. T. (2026) · Journal of Biologically Active Products from Nature · doi:10.1080/22311866.2025.2610615
Tarbiat, S., Yurdakul, T., Kantarci-Carsibasi, N., Işık, S., & Güven, N. (2026) · Türk Tarım ve Doğa Bilimleri Dergisi · doi:10.30910/turkjans.1736650
Roy, G., Lingaraj, P., Periyasamy, T. S., Chandrasekar, A. K., Sekar, N., & Lakshmanan, H. (2026) · In Silico Pharmacology · doi:10.1007/s40203-026-00556-0 · Cited by 1
Radiofrequency electromagnetic fields in Alzheimer’s therapy: emerging evidence and future prospects
Liu, W., Rao, X., Sun, W., Chen, X., Yu, L., & Zhang, J. (2026) · Electromagnetic Biology and Medicine · doi:10.1080/15368378.2026.2627962
Responsible AI for Health Governance: A Focus on Alzheimer's Patients
Garg, M., Juneja, A., Painuli, D., Mishra, D., Kumari, P., & Kumar, V. (2025) · International Conference on Innovations and Emerging Technologies in AI & Communication Systems (IETACS) · doi:10.1109/ietacs68750.2025.11385450
Recent advances in the total synthesis of bioactive natural products using ultrasound
Majhi, S., & Sivakumar, M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27482-4.00014-9
Development of Inhibitors of Amyloid Fibril Propagation
Bendifallah, M. (2019) · theses.fr (ABES) · doi:10.70675/a872e5bdzc153z41f4z9472z725fd78aab48
Rauf, A., Ibrahim, M., Al-Awthan, Y. S., Bahattab, O. S., Hemeg, H. A., Khalil, A. A., Khalid, A., Shahid, S., Gull, H., Jan, M. S., et al. (2026) · Plant Biosystems - An International Journal Dealing with all Aspects of Plant Biology · doi:10.1007/s44473-026-00141-5
Han, K. S. S., Lv, Y., Xie, D., Zou, L.-H., Jiang, Q., Xie, S., Zhang, Y., Zhao, P., Yang, X.-Q., & Wee, S. K. (2026) · Chemistry & Biodiversity · doi:10.1002/cbdv.202503013
A narrative review on preclinical/clinical trials on aducanumab
Goel, A., Garima, G., Jain, P., Bansal, S., Chopra, H., Gupta, S., Kumar, S., Dhanawat, M., & Aggarwal, N. (2026) · Scripta Medica · doi:10.5937/scriptamed57-59386
de Andrade, E. J. N., Salles, G. N., Giraldi, L. D. A., Sudo, M. Y. R., Ramos, L. D. P., & Soares, C. P. (2026) · In vitro models · doi:10.1007/s44164-026-00129-7
Weon, J. B., Kim, S., Kim, J., Park, S.-J., & Ma, C. J. (2026) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2026.146857
Olajide, A. T., Aunsorn, S., Kehinde, S. A., Kaewmanee, T., & Chusri, S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27125488
Gupta, S., Adhikary, T., Das, P., & Basak, P. (2026) · Letters in Drug Design & Discovery · doi:10.1016/j.lddd.2026.100452
Jóźwicka, A., Janikowski, W., Bąkowska, E., Stępka, A., Jaworowicz, L., Plichtowicz-Kordowska, W., Lewandowska, K., Awad, S., Szymonek, P., & Zysk, A. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5914
Herbal Drugs and their Active Phytoconstituents used for the Treatment of Alzheimer’s and Dementia
Jain, S. K., Trivedi, R., Goyal, S., Sivchandan, A., MUDGAL, K., Modi, P., & Gandhi, S. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898815523126010007
Alzheimer’s Disease: Molecular Pathophysiology and Current Therapeutic Management
Shingade, S. S., Mandhare, T. A., Mujumale, J. S., Kashid, P., & Otari, K. V. (2026) · Biosciences Biotechnology Research Asia · doi:10.13005/bbra/3523
Xue, H., Zhu, X., & Hao, H. (2026) · Pharmacognosy Magazine · doi:10.1177/09731296261466884
Kamran, Q., & BARETTO, P. (2026) · Springer eBooks · doi:10.1007/978-3-032-20997-9_9
42311 Heck reaction in natural product total synthesis
Majhi, S. (2026) · De Gruyter eBooks · doi:10.1515/9783111739601-012
Piplani, M., Thakur, S., Kumar, P., Garg, S. S., Goyal, A., & Goyal, P. (2026) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/3483
A Hierarchical Framework for In Vitro Models of Alzheimer's Disease
Balverde‐Caballero, F. B., Pérez‐Tur, J., & Cardona, F. (2026) · WIREs Mechanisms of Disease · doi:10.1002/wsbm.70015
Molecular mechanisms of drug resistance in brain therapy
Mude, G., Sheikh, D. M. T., Bhope, S., Nagdev, S. A., & Borkar, S. S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44117-2.00017-7
Achanti, S., Prasanth, D., Pasala, P. K., Narla, D., Aswatha, B., Syamala, J. Y. P., Jonnalagadda, S., & Supriya, N. (2026) · ChemistrySelect · doi:10.1002/slct.74921
BindingDB (2022) · UC San Diego · doi:10.7270/q24171ns
BindingDB Entry 50015932: High ligand efficiency quinazoline compounds as novel A
BindingDB (2023) · UC San Diego · doi:10.7270/q2g44v8s
BindingDB (2023) · UC San Diego · doi:10.7270/q2h70kvx
Metadata
- Authors
- Yiannopoulou, K. G., & Papageorgiou, S. G.
- Affiliations
- Laiko General Hospital of Athens (GR)
- National and Kapodistrian University of Athens (GR)
- Venue
- Therapeutic Advances in Neurological Disorders
- Publisher
- SAGE Publications
- Published
- 2012-10-15
- Volume
- 6
- Issue
- 1
- Pages
- 19-33
- ISSN
- 1756-2856 (ISSN-L)
- 1756-2864
- PMC
- PMC3526946
- OpenAlex
- W1987204546
- Cited by
- 677
- References
- 83
- Citations by year
- 2026: 35 · 2025: 55 · 2024: 66 · 2023: 70 · 2022: 84 · 2021: 81 · 2020: 83 · 2019: 61 · 2018: 45 · 2017: 37 · 2016: 27 · 2015: 9 · 2014: 9 · 2013: 14
- FWCI
- 6.86
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Therapeutic Advances in Neurological Disorders (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, cholinesterase inhibitors, memantine, disease-modifying therapy, symptomatic treatment, amyloid plaques, neurofibrillary tangles, oxidative stress, neuroinflammation, cholesterol metabolism, NMDA receptor antagonists, clinical trials
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
